PBLS — Parabilis Medicines Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Parabilis Medicines, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2024 December 31st | 2025 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Net Income/Starting Line | -118 | -146 |
| Depreciation | ||
| Non-Cash Items | 11.3 | 10.6 |
| Unusual Items | ||
| Other Non-Cash Items | ||
| Changes in Working Capital | 0.91 | 9.12 |
| Change in Accounts Receivable | ||
| Change in Prepaid Expenses | ||
| Change in Accounts Payable | ||
| Change in Accrued Expenses | ||
| Change in Payable / Accrued Expenses | ||
| Cash from Operating Activities | -104 | -124 |
| Capital Expenditures | -0.879 | -0.306 |
| Purchase of Fixed Assets | ||
| Other Investing Cash Flow Items | 31.1 | 40.1 |
| Sale/Maturity of Investment | ||
| Purchase of Investments | ||
| Cash from Investing Activities | 30.2 | 39.8 |
| Financing Cash Flow Items | -0.511 | -0.062 |
| Other Financing Cash Flow | ||
| Net Issuance / Retirement of Stock | ||
| Net Issuance / Retirement of Debt | ||
| Cash from Financing Activities | 78.1 | 64.4 |
| Beginning Cash Balance | ||
| Ending Cash Balance | ||
| Net Change in Cash | 4.7 | -19.6 |